We’ve already made sure our investing fees are some of the lowest in the market, but we know that the fees that come with investing can be one of the things that can make our members pause for thought.

So, we’re offering a free trial of our ChipX plan (with its 0% platform fees for investing) for 12 months if you unlock it before 10 January 2025. 

There’s no commitment to stay on ChipX or keep investing with us and you can opt out at any time. 

But whatever you decide to do, after your trial ends you’ll enjoy some of the lowest fees for investing in the market - either one simple fixed subscription with ChipX (£5.99 /28 days), or a 0.25% platform fee on our standard plan. 

‍

How to get the free trial:

• Simply upgrade to ChipX by following the steps in your Profile tab 

‍

How the free trial works:

• You can get a 365 day free trial of ChipX which begins from the day you upgrade
• This offer is running until 10 January 2025 (terms apply)

‍

What you get:

• ChipX has 0% platform fees and no transaction fees for investing
• So effectively we’re giving you free access to our investment platform for 365 days 
• But note, fund management fees still apply (these vary from fund to fund and are charged directly by the fund manager e.g. BlackRock, Vanguard, Invesco etc…)

‍

Who can unlock the free trial?

• The 12 month free trial is open to people who don’t invest with us already, and;
• Not already on ChipX, ChipX investor, or a ChipX free trial as of 13 November 2024

‍

What happens when the free trial ends?

• After your trial ends you will be billed the ChipX subscription (£5.99 a month every 28 days, or pay less on an annual subscription).
• There’s no obligation to stay on ChipX, you can opt out at any time. 
• But note you won’t be able to add more money to any of your ChipX exclusive funds if you downgrade. 

‍

When investing, your capital is at risk. The value of your investments may go down as well as up and you may get less back than your original investment. Chip does not provide financial advice.

‍